Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F23%3A10466294" target="_blank" >RIV/00669806:_____/23:10466294 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10466294 RIV/00216208:11110/23:10466294 RIV/00216208:11140/23:10466294 RIV/00179906:_____/23:10466294 and 2 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=0lEI.w6vbr" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=0lEI.w6vbr</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.23736/S2724-6051.23.05369-7" target="_blank" >10.23736/S2724-6051.23.05369-7</a>
Alternative languages
Result language
angličtina
Original language name
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
Original language description
BACKGROUND: The upfront treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by the introduction of immune-based combinations. The role of cytoreductive nephrectomy (CN) in these patients is still debated. The ARON-1 study (NCT05287464) was designed to globally analyze real-world data of mRCC patients receiving first-line immuno-oncology combinations. This sub-analysis is focused on the role of upfront or delayed partial or radical CN in three geographical areas (Western Europe, Eastern Europe, America/Asia). METHODS: We conducted a multicenter retrospective observational study in mRCC patients treated with first-line immune combinations from 55 centers in 19 countries. From 1152 patients in the ARON-1 dataset, we selected 651 patients with de novo mRCC. 255 patients (39%) had undergone CN, partial in 14% and radical in 86% of cases; 396 patients (61%) received first-line immune-combinations without previous nephrectomy. RESULTS: Median overall survival (OS) from the diagnosis of de novo mRCC was 41.6 months and not reached (NR) in the CN subgroup and 24.0 months in the no CN subgroup, respectively (P<0.001). Median OS from the start of first-line therapy was NR in patients who underwent CN and 22.4 months in the no CN subgroup (P<0.001). Patients who underwent CN reported longer OS compared to no CN in all the three geographical areas. CONCLUSIONS: No significant differences in terms of patients' outcome seem to clearly emerge, even if the rate CN and the choice of the type of first-line immune-based combination varies across the different Cancer Centers participating in the ARON-1 project.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Minerva Urology and Nephrology
ISSN
2724-6051
e-ISSN
2724-6442
Volume of the periodical
75
Issue of the periodical within the volume
4
Country of publishing house
IT - ITALY
Number of pages
11
Pages from-to
460-470
UT code for WoS article
001058713800007
EID of the result in the Scopus database
2-s2.0-85166137512